Rosuvastatin intermediates and process for the preparation of rosuvastatin

a technology of rosuvastatin and rosuvastatin, which is applied in the field of rosuvastatin intermediates and process for the preparation of rosuvastatin, can solve the problems of difficult purification of tsph by column chromatography, process problems, and unsatisfactory industrial processes

Inactive Publication Date: 2009-03-19
TEVA PHARM USA INC
View PDF10 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The process of WO 03/087112 may not be desirable on an industrial scale because it requires the use of an expensive microorganism, such as CLS-BC-14011, during the partial hydrolysis of 3-hydroxy diethyl glutarate.
Additionally, the process uses hazardous materials, such as isobutylene gas, during esterification of ethyl-(3S)-3-hydroxyglutaric acid in the presence of sulphuric acid.
Also, the purification of TSPH by column chromatography is ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rosuvastatin intermediates and process for the preparation of rosuvastatin
  • Rosuvastatin intermediates and process for the preparation of rosuvastatin
  • Rosuvastatin intermediates and process for the preparation of rosuvastatin

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of 3-Hydroxy Dihydrogen Glutarate (TBDMS Protected) (Protected Diacid) from 3-Hydroxy Diethyl Glutarate (TBDMS Protected) Through Hydrolysis (Formula V from Hydrolysis of Formula IV)

[0117]To a 5-liter four neck round bottom flask under nitrogen atmosphere added 163 g 3-hydroxy diethyl glutarate (TBDMS protected) and 815 ml methanol at 25 to 30° C., and added 45.10 g sodium hydroxide with 326 ml water to the reaction mass over the period of 1 hr at 30 to 32° C. Stirred reaction mass at 30 to 32° C. Starting material was not detected after 24 hr by TLC. White colored disodium salt was observed. Added 500 g 10% hydrochloric acid solution to adjust pH of reaction mass to 3.5 to produce a clear solution. Added 275 g sodium chloride to saturate reaction mass and extracted product in 4×650 ml dichloromethane, evaporated solvent under vacuum at 40 to 50° C. to get white colored crude product which was further stirred with 600 ml hexane and filtered. Dry the product under vacuum ...

example 2

Preparation of 3-Hydroxy Glutaric Anhydride (TBDMS Protected) from 3-Hydroxy Dihydrogen Glutarate (TBDMS Protected) (Formula VI from Formula V)

[0119]To a 2-liter four neck round bottom flask under nitrogen atmosphere added 180 g solid 3-hydroxy dihydrogen glutarate (TBDMS protected) and 630 ml acetic anhydride at 25 to 30° C. and reflux reaction mass for 2 hr at 130-135° C. Monitored by TLC and GC, starting material was not found in 2.0 hr. Acetic anhydride was distilled under vacuum at 75-80° C. completely and crude product was crystallized through 180 ml hexane and dried pure brown colored product under vacuum at 40° C. Obtained 171 g pure product.

[0120]Yield 100% purity 99.5% (Area % by GC)

example 3

Preparation of Racemic Methyl Hydrogen 3-Hydroxy Glutarate (TBDMS Protected) From 3-Hydroxy Glutaric Anhydride (TBDMS Protected) (Formula VII from Formula VI)

[0121]To a 2-liter four neck round bottom flask under nitrogen atmosphere added 20 g 3-hydroxy glutaric anhydride (TBDMS protected), 200 ml methanol and reflux reaction mass for 12 hr at 60 to 65° C. Monitored reaction progress by GC, starting material was not detected. Allowed reaction mass temperature up to room temperature (“RT”) and added 2-3 drop of hydrochloric acid and 100 ml water. Added sodium chloride to saturate reaction mass at room temperature. Extracted product with 200 ml dichloromethane. Aqueous layer was extracted with 20 ml dichloromethane and combined organic layer was dried over sodium sulphate. Solvent was evaporated to give 20.0 g product.

[0122]Yield 88.4% purity 94.5% (Area % by GC)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Lengthaaaaaaaaaa
Lengthaaaaaaaaaa
Lengthaaaaaaaaaa
Login to view more

Abstract

Provided are intermediates and process for the preparation of statins, preferably rosuvastatin.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application No. 60 / 925,216, filed Apr. 18, 2007; 60 / 931,926, filed May 24, 2007; 61 / 066,678, filed Feb. 21, 2008, and 61 / 069,099, filed Mar. 11, 2008. The contents of which are incorporated herein by reference.FIELD OF THE INVENTION[0002]The invention relates to the preparation of chirally pure rosuvastatin intermediates and to the preparation of rosuvastatin and pharmaceutically acceptable salts thereof.BACKGROUND OF INVENTION[0003]Rosuvastatin calcium has the chemical name (7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-6-heptenoic acid calcium salt), and has the following chemical formula:Rosuvastatin calcium is an HMG-CoA reductase inhibitor, developed by Shionogi for the once daily oral treatment of hyperlipidaemia (Ann Rep, Shionogi, 1996; Direct communications, Shionogi, 8 Feb. 1999 & 25 Feb. 2000). Rosuvastatin calciu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07F7/02C07C69/67
CPCC07F7/1856C07F9/5352C07F9/4006C07F7/1804A61P3/06A61P43/00C07F7/18
Inventor KANSAL, VINOD KUMARRANJAN, HARISHJAWARE, JALINDER N.PONNUSWAMY, APPU EKAMBARAM
Owner TEVA PHARM USA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap